AKYA Akoya Biosciences, Inc.: Forward P/S Multiple

Akoya Biosciences (AKYA) generates revenue through the sale of PhenoCycler systems and associated reagents. Demand for tumor protein analysis tools is driven by pharmaceutical centers and research institutes. The forward P/S trajectory based on GURU.Markets data demonstrates the influence of these factors, where the 0.80 level captures the current state. The company's environmental profile is based on electronics recycling and office energy efficiency.

Akoya Biosciences, Inc. - AKYA Market Cap to Expected Sales Ratio (period 07/04/2022 - 07/19/2025)

Metric breakdowns and analytics for Akoya Biosciences Inc (AKYA)

- current price and projected stock value:

Stock Price Akoya Biosciences, Inc.|AKYA - Average Forecast Price

- company stock capitalization data:

Market Capitalization Akoya|AKYA - Business Value

- issuer book value statistics:

Book Value per Share Akoya Biosciences|AKYA - Book Valuation of Business|Market Capitalization to Book Value Ratio akoyabio.com|AKYA - Cumulative Company Assets

- company total debt and liquidity indicators:

- financial results and valuation multiples details:

AKYA - Annual Net Income|Future Profit Akoya Biosciences|AKYA - P/E Multiple|Forward P/E Multiple akoyabio.com|AKYA - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Akoya Biosciences|AKYA - Profit before deduction of interest, taxes, depreciation and amortization|Earnings per share for the last twelve months Akoya Biosciences|AKYA - Net earnings per share for the last 12 months|Quarterly EPS earnings growth akoyabio.com|AKYA - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Akoya Biosciences

- sales volume and revenue indicators:

AKYA - Company Sales Volume|Company Future Sales Volume Akoya Biosciences, Inc.|AKYA - Market Cap to Sales Volume|Forward P/S Multiple Akoya Biosciences

Summary company analytics:Akoya Biosciences, Inc. (AKYA)

Product sample of Akoya Biosciences, Inc.

This indicator assesses investment reliability via the ratio of market capitalization to expected revenue, filtering out short-term volatility by smoothing price fluctuations. By analyzing the forward P/S ratio, an investor can identify the potential for multiple compression, which in the case of Akoya Biosciences (AKYA) is offset by a "razor-and-blade" model, where equipment sales guarantee a steady stream of high-margin revenue from the sale of consumables.

Key competitors

Forward P/S Multiple ABT (Abbott Laboratories)|TMO: Market Cap to Projected Revenue|GE HealthCare Technologies - Forward P/S Multiple|Market Cap to Expected Sales Ratio Mettler-Toledo International MTD|WAT: Forward P/S Multiple|TECH - Market Cap to Expected Sales Ratio|BRKR (Bruker BioSpin) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Azenta Life Sciences (AZTA)|Forward P/S Multiple VREX|Forward P/S Multiple semlerscientific.com (SMLR)|Price-to-Projected Revenue Ratio Butterfly Network BFLY|Mesa Labs Corp - Price-to-Projected Revenue Ratio|quantum-si.com - Forward P/S Multiple|Forward Price to Sales NNOX (Nanox)|QTRX: Forward P/S Multiple|Market Cap to Future Revenue Ratio 908devices.com (MASS)|CV (CapsoVision) - Forward P/S Multiple|MXCT - Projected Price to Revenue|Forward Price-to-Revenue Multiple RPID (rapidmicrobio.com)|Forward P/S Multiple Seer Inc. (SEER)|Forward P/S Multiple HYPR (hyperfine.io)|Market Cap to Expected Sales Ratio fonar.com (FONR)|DXR - Price-to-Projected Revenue Ratio|Future Price to Revenue MDAI|Organovo Holdings (VIVS) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Aclarion Corp|THMO (ThermoGenesis Holdings, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio talis.bio TLIS|Price-to-Projected Revenue Ratio T2 Biosystems, Inc (TTOO)